DiaMedica Therapeutics, Inc. (NASDAQ:DMAC) Given Average Recommendation of “Moderate Buy” by Brokerages

DiaMedica Therapeutics, Inc. (NASDAQ:DMAC) has received an average recommendation of “Moderate Buy” from the five brokerages that are covering the firm, MarketBeat reports. One analyst has rated the stock with a sell rating and four have assigned a buy rating to the company. The average twelve-month target price among brokers that have issued ratings on the stock in the last year is $12.00.

A number of research analysts have recently issued reports on DMAC shares. Weiss Ratings reissued a “sell (d-)” rating on shares of DiaMedica Therapeutics in a research note on Friday, July 17th. Wall Street Zen raised DiaMedica Therapeutics from a “strong sell” rating to a “sell” rating in a research note on Saturday, June 6th.

Institutional Trading of DiaMedica Therapeutics

Large investors have recently modified their holdings of the stock. Millennium Management LLC acquired a new stake in shares of DiaMedica Therapeutics during the 3rd quarter worth approximately $8,157,000. Geode Capital Management LLC lifted its position in shares of DiaMedica Therapeutics by 99.6% during the 2nd quarter. Geode Capital Management LLC now owns 630,148 shares of the company’s stock valued at $2,458,000 after acquiring an additional 314,407 shares during the period. Royal Bank of Canada boosted its stake in DiaMedica Therapeutics by 46,879.1% during the first quarter. Royal Bank of Canada now owns 155,031 shares of the company’s stock worth $588,000 after acquiring an additional 154,701 shares in the last quarter. State Street Corp boosted its stake in DiaMedica Therapeutics by 31.7% during the fourth quarter. State Street Corp now owns 627,771 shares of the company’s stock worth $4,997,000 after acquiring an additional 151,188 shares in the last quarter. Finally, Osaic Holdings Inc. grew its holdings in DiaMedica Therapeutics by 374.7% in the second quarter. Osaic Holdings Inc. now owns 144,290 shares of the company’s stock worth $563,000 after purchasing an additional 113,893 shares during the period. Institutional investors and hedge funds own 10.12% of the company’s stock.

DiaMedica Therapeutics Stock Down 2.6%

DMAC stock opened at $6.34 on Friday. The firm has a market cap of $341.60 million, a price-to-earnings ratio of -8.93 and a beta of 0.97. The company’s fifty day simple moving average is $6.54 and its 200 day simple moving average is $7.01. DiaMedica Therapeutics has a 12-month low of $4.01 and a 12-month high of $10.42.

DiaMedica Therapeutics (NASDAQ:DMAC) last issued its quarterly earnings results on Wednesday, May 6th. The company reported ($0.19) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.17) by ($0.02). Research analysts expect that DiaMedica Therapeutics will post -0.86 earnings per share for the current year.

About DiaMedica Therapeutics

DiaMedica Therapeutics, Inc (NASDAQ: DMAC) is a clinical‐stage biopharmaceutical company focused on developing novel therapies for acute and chronic central nervous system conditions. The company’s lead product candidate, DM199, is a recombinant form of human tissue kallikrein-1 designed to promote neuroprotection and tissue repair through modulation of the kallikrein‐kinin system. DiaMedica’s research and development efforts are centered on translating the regenerative potential of DM199 into effective treatments for disorders with high unmet medical need.

DM199 is being evaluated in acute ischemic stroke, where preclinical studies have demonstrated potential benefits in blood flow restoration, inflammation reduction and neuronal survival.